Reactive microglia drive tau pathology and contribute to the spreading of pathological tau in the brain.

Pathological aggregation of tau is a hallmark of Alzheimer's disease and related tauopathies. We have previously shown that the deficiency of the microglial fractalkine receptor (CX3CR1) led to the acceleration of tau pathology and memory impairment in an hTau mouse model of tauopathy. Here, we show that microglia drive tau pathology in a cell-autonomous manner. First, tau hyperphosphorylation and aggregation occur as early as 2 months of age in hTauCx3cr1(-/-) mice. Second, CD45(+) microglial activation correlates with the spatial memory deficit and spread of tau pathology in the anatomically connected regions of the hippocampus. Third, adoptive transfer of purified microglia derived from hTauCx3cr1(-/-) mice induces tau hyperphosphorylation within the brains of non-transgenic recipient mice. Finally, inclusion of interleukin 1 receptor antagonist (Kineret®) in the adoptive transfer inoculum significantly reduces microglia-induced tau pathology. Together, our results suggest that reactive microglia are sufficient to drive tau pathology and correlate with the spread of pathological tau in the brain.

[1]  P. Gebicke-haerter.  Microglia in neurodegeneration: Molecular aspects , 2001, Microscopy research and technique.

[2]  K. Takamatsu,et al.  Inhibitors of p38 mitogen‐activated protein kinase enhance proliferation of mouse neural stem cells , 2008, Journal of neuroscience research.

[3]  Meaghan Morris,et al.  The Many Faces of Tau , 2011, Neuron.

[4]  Alexander Gerhard,et al.  In vivo imaging of microglial activation with [11C](R)‐PK11195 PET in progressive supranuclear palsy , 2006, Movement disorders : official journal of the Movement Disorder Society.

[5]  A. McKee,et al.  Exosome-associated Tau Is Secreted in Tauopathy Models and Is Selectively Phosphorylated in Cerebrospinal Fluid in Early Alzheimer Disease* , 2011, The Journal of Biological Chemistry.

[6]  K. Herrup,et al.  Microglial derived tumor necrosis factor-α drives Alzheimer's disease-related neuronal cell cycle events , 2014, Neurobiology of Disease.

[7]  R. Morris.  Developments of a water-maze procedure for studying spatial learning in the rat , 1984, Journal of Neuroscience Methods.

[8]  J. Serratosa,et al.  High‐yield isolation of murine microglia by mild trypsinization , 2003, Glia.

[9]  Nick C Fox,et al.  Common variants in ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease , 2011, Nature Genetics.

[10]  R. Mrak,et al.  Interleukin-1 promotion of MAPK-p38 overexpression in experimental animals and in Alzheimer's disease: potential significance for tau protein phosphorylation , 2001, Neurochemistry International.

[11]  Patrick L. McGeer,et al.  Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease , 1996, Neurology.

[12]  H. Braak,et al.  Demonstration of Amyloid Deposits and Neurofibrillary Changes in Whole Brain Sections , 1991, Brain pathology.

[13]  A. Sher,et al.  Analysis of Fractalkine Receptor CX3CR1 Function by Targeted Deletion and Green Fluorescent Protein Reporter Gene Insertion , 2000, Molecular and Cellular Biology.

[14]  P. Davies,et al.  Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms , 2003, Journal of neurochemistry.

[15]  A. McKee,et al.  The spectrum of disease in chronic traumatic encephalopathy. , 2013, Brain : a journal of neurology.

[16]  W. Noble,et al.  Kinase activities increase during the development of tauopathy in htau mice , 2007, Journal of neurochemistry.

[17]  Menno P. Witter,et al.  Trans-Synaptic Spread of Tau Pathology In Vivo , 2012, PloS one.

[18]  Patrick L. McGeer,et al.  Inflammation, autotoxicity and Alzheimer disease , 2001, Neurobiology of Aging.

[19]  W. Rostène,et al.  Current status of chemokines in the adult CNS , 2013, Progress in Neurobiology.

[20]  H. Levin,et al.  Cognitive impairment following closed head injury. , 1992, Neurologic clinics.

[21]  Yoo-Hun Suh,et al.  Increased tau Phosphorylation on Mitogen-Activated Protein Kinase Consensus Sites and Cognitive Decline in Transgenic Models for Alzheimer's Disease and FTDP-17: Evidence for Distinct Molecular Processes Underlying tau Abnormalities , 2005, Molecular and Cellular Biology.

[22]  M. Goedert,et al.  Molecular Pathogenesis of Genetic and Inherited Diseases Induction of Inflammatory Mediators and Microglial Activation in Mice Transgenic for Mutant Human P301S Tau Protein , 2004 .

[23]  R. Ransohoff,et al.  CX3CR1 Protein Signaling Modulates Microglial Activation and Protects against Plaque-independent Cognitive Deficits in a Mouse Model of Alzheimer Disease* , 2011, The Journal of Biological Chemistry.

[24]  E Friedman,et al.  Age-associated impairment in brain MAPK signal pathways and the effect of caloric restriction in Fischer 344 rats. , 1999, The journals of gerontology. Series A, Biological sciences and medical sciences.

[25]  A. Singleton,et al.  TREM2 variants in Alzheimer's disease. , 2013, The New England journal of medicine.

[26]  F. LaFerla,et al.  Sustained Interleukin-1β Overexpression Exacerbates Tau Pathology Despite Reduced Amyloid Burden in an Alzheimer's Mouse Model , 2013, The Journal of Neuroscience.

[27]  Koji Abe,et al.  Accumulation of filamentous tau in the cerebral cortex of human tau R406W transgenic mice. , 2005, The American journal of pathology.

[28]  A. Singleton,et al.  TREM2 Variants in Alz hei mer's Disease , 2012 .

[29]  F. Martinon,et al.  New insights into the mechanism of IL-1β maturation , 2003 .

[30]  N. Rothwell,et al.  Interleukin-1 Receptor Antagonist Penetrates Human Brain at Experimentally Therapeutic Concentrations , 2008, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[31]  B. Ghetti,et al.  Presence of Reactive Microglia and Neuroinflammatory Mediators in a Case of Frontotemporal Dementia with P301S Mutation , 2011, Neurodegenerative Diseases.

[32]  D. Selkoe.  Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[33]  C. Caltagirone,et al.  Effect of Proinflammatory Gene Polymorphisms on the Risk of Alzheimer's Disease , 2013, Neurodegenerative Diseases.

[34]  J. Cui,et al.  Expression of inflammatory genes in the primary visual cortex of late-stage Alzheimer's disease , 2007, Neuroreport.

[35]  C. Limatola,et al.  CX3CR1 Deficiency Alters Hippocampal-Dependent Plasticity Phenomena Blunting the Effects of Enriched Environment , 2011, Front. Cell. Neurosci..

[36]  D. Westaway,et al.  Microglial activation in brain lesions with tau deposits: Comparison of human tauopathies and tau transgenic mice TgTauP301L , 2008, Brain Research.

[37]  P. Bickford,et al.  CX3CR1 Deficiency Leads to Impairment of Hippocampal Cognitive Function and Synaptic Plasticity , 2011, The Journal of Neuroscience.

[38]  B. Lamb,et al.  The Role of Aβ and Tau Oligomers in the Pathogenesis of Alzheimer’s Disease , 2012 .

[39]  D. Dickson,et al.  Microglial Activation Parallels System Degeneration in Progressive Supranuclear Palsy and Corticobasal Degeneration , 2001, Journal of neuropathology and experimental neurology.

[40]  A. Hofman,et al.  Variant of TREM2 associated with the risk of Alzheimer's disease. , 2013, The New England journal of medicine.

[41]  Bin Zhang,et al.  Synapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model , 2007, Neuron.

[42]  G. Bitan,et al.  Non-fibrillar Amyloidogenic Protein Assemblies - Common Cytotoxins Underlying Degenerative Diseases , 2012, Springer Netherlands.

[43]  Patrick L. McGeer,et al.  NSAIDs and Alzheimer disease: Epidemiological, animal model and clinical studies , 2007, Neurobiology of Aging.

[44]  M. Arfan Ikram,et al.  Variant of TREM 2 Associated with the Risk of Alzheimer ’ s Disease , 2012 .

[45]  P. Bosco,et al.  Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease , 2009, Nature Genetics.

[46]  Genetic polymorphism of interleukin 1β −511C/T and susceptibility to sporadic Alzheimer’s disease: a meta-analysis , 2013, Molecular Biology Reports.

[47]  Steffen Jung,et al.  Control of microglial neurotoxicity by the fractalkine receptor , 2006, Nature Neuroscience.

[48]  Rebecca Burwell,et al.  Severity of spatial learning impairment in aging: Development of a learning index for performance in the Morris water maze. , 1993, Behavioral neuroscience.

[49]  Nick C Fox,et al.  Common variants at ABCA 7 , MS 4 A 6 A / MS 4 A 4 E , EPHA 1 , CD 33 and CD 2 AP are associated with Alzheimer ’ s disease , 2011 .

[50]  Tony Wyss-Coray,et al.  Inflammation in Alzheimer disease: driving force, bystander or beneficial response? , 2006, Nature Medicine.

[51]  R. Ransohoff,et al.  Regulation of Tau Pathology by the Microglial Fractalkine Receptor , 2010, Neuron.

[52]  Lloyd Demetrius,et al.  Aging in Mouse and Human Systems , 2006, Annals of the New York Academy of Sciences.

[53]  M. Diamond,et al.  Propagation of Tau Misfolding from the Outside to the Inside of a Cell* , 2009, Journal of Biological Chemistry.

[54]  P. Davies,et al.  A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[55]  Alexander Gerhard,et al.  In vivo imaging of microglial activation with [11C](R)‐PK11195 PET in corticobasal degeneration , 2004, Movement disorders : official journal of the Movement Disorder Society.

[56]  J. Tschopp,et al.  The Inflammasomes , 2010, Cell.

[57]  Antonella Plaia,et al.  Association between the interleukin-1β polymorphisms and Alzheimer's disease: A systematic review and meta-analysis , 2008, Brain Research Reviews.

[58]  C. Morissette,et al.  Inflammation occurs early during the Aβ deposition process in TgCRND8 mice , 2004, Neurobiology of Aging.

[59]  F. Martinon,et al.  New insights into the mechanism of IL-1beta maturation. , 2003, Current opinion in immunology.

[60]  Jerry L. Adams,et al.  A protein kinase involved in the regulation of inflammatory cytokine biosynthesis , 1994, Nature.

[61]  N. Zilka,et al.  Human misfolded truncated tau protein promotes activation of microglia and leukocyte infiltration in the transgenic rat model of tauopathy , 2009, Journal of Neuroimmunology.

[62]  K. J. Murphy,et al.  Neuron–glia crosstalk in health and disease: fractalkine and CX3CR1 take centre stage , 2013, Open Biology.

[63]  W. Lukiw.  Gene Expression Profiling in Fetal, Aged, and Alzheimer Hippocampus: A Continuum of Stress-Related Signaling , 2004, Neurochemical Research.

[64]  F. LaFerla,et al.  Lipopolysaccharide-Induced Inflammation Exacerbates Tau Pathology by a Cyclin-Dependent Kinase 5-Mediated Pathway in a Transgenic Model of Alzheimer's Disease , 2005, The Journal of Neuroscience.

[65]  Q. Yao,et al.  Microglia exhibit clonal variability in eliciting cytotoxic T lymphocyte responses independent of class I expression. , 1999, Cellular immunology.

[66]  References , 1971 .

[67]  Who fans the flames of Alzheimer's disease brains? Misfolded tau on the crossroad of neurodegenerative and inflammatory pathways , 2012, Journal of Neuroinflammation.

[68]  F. LaFerla,et al.  Blocking IL-1 Signaling Rescues Cognition, Attenuates Tau Pathology, and Restores Neuronal β-Catenin Pathway Function in an Alzheimer’s Disease Model , 2011, The Journal of Immunology.

[69]  R. Ransohoff,et al.  The myeloid cells of the central nervous system parenchyma , 2010, Nature.

[70]  Paul W. Frankland,et al.  Frontiers in Integrative Neuroscience Integrative Neuroscience , 2022 .

[71]  J. Trojanowski,et al.  Neurodegenerative tauopathies. , 2001, Annual review of neuroscience.

[72]  S. Barger,et al.  Interleukin-1 Mediates Pathological Effects of Microglia on Tau Phosphorylation and on Synaptophysin Synthesis in Cortical Neurons through a p38-MAPK Pathway , 2003, The Journal of Neuroscience.

[73]  D. G. Clark,et al.  Common variants in MS4A4/MS4A6E, CD2uAP, CD33, and EPHA1 are associated with late-onset Alzheimer’s disease , 2011, Nature Genetics.

[74]  Z. Környei,et al.  Role of CX3CR1 (Fractalkine Receptor) in Brain Damage and Inflammation Induced by Focal Cerebral Ischemia in Mouse , 2008, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[75]  Urs Meyer,et al.  Systemic immune challenges trigger and drive Alzheimer-like neuropathology in mice , 2012, Journal of Neuroinflammation.

[76]  E. Masliah,et al.  Mechanisms of cell signaling and inflammation in Alzheimer's disease. , 2005, Current drug targets. Inflammation and allergy.

[77]  C. Bradham,et al.  p38 MAPK in Development and Cancer , 2006, Cell cycle.

[78]  L. Kiemeney,et al.  Corrigendum: Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer , 2009, Nature Genetics.

[79]  Nick C Fox,et al.  Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease, and shows evidence for additional susceptibility genes , 2009, Nature Genetics.

[80]  M. Fornerod,et al.  Characterization of the Drosophila melanogaster genome at the nuclear lamina , 2006, Nature Genetics.

[81]  P. Hof,et al.  Cell-Cycle Reentry and Cell Death in Transgenic Mice Expressing Nonmutant Human Tau Isoforms , 2005, The Journal of Neuroscience.

[82]  M. Ball,et al.  Gene expression profiling of 12633 genes in Alzheimer hippocampal CA1: Transcription and neurotrophic factor down‐regulation and up‐regulation of apoptotic and pro‐inflammatory signaling , 2002, Journal of neuroscience research.

[83]  L. Forsman,et al.  Tick-borne encephalitis carries a high risk of incomplete recovery in children. , 2013, The Journal of pediatrics.

[84]  P. Bertolucci,et al.  Association of interleukin 1β polymorphisms and haplotypes with Alzheimer's disease , 2012, Journal of Neuroimmunology.